While plasma levels of CC16 and SP-D remained constant in VAP patients who did not develop ALI/ARDS, plasma levels of these pulmonary proteins increased in patients who eventually developed ALI/ARDS. This evidence concerns the gene SFTPD and acute respiratory distress syndrome.